Navigation Links
STD Med, Inc. Receives Second Brazil GP Approval And Adds Med-Tech Regulatory Consulting Service
Date:5/3/2013

STOUGHTON, Mass., May 3, 2013 /PRNewswire/ -- STD Med, Inc. is pleased to announce that it has received a second Certificate of Good Practices for Manufacturing of Class III Medical Devices from ANVISA, the Brazilian National Surveillance Agency (Agencia Nacional de Vigilancia Sanitaria –ANVISA). All medical devices must be registered with ANVISA before being sold in Brazil. The Certificate of Good Practices was granted to STD Med after an intensive audit by the Brazilian agency. The audit process is a comprehensive inspection of policies, procedures and facilities and can often take a number of years to complete. It is one of the primary hurdles for new medical device product registration in Brazil.

SyncMedical LLC, a subsidiary of STD Med, Inc., worked in partnership with Sinnergy Medical, one of its Brazilian distributors, to achieve approval in less than four months. "SyncMedical is uniquely positioned to further assist in establishing emerging new technologies in Brazil," said Steven Tallarida , President of both STD Med, Inc. and SyncMedical LLC, "with a distribution network of 13 offices in Brazil, SyncMedical has the ability to establish medical device sales and marketing support for any U.S. based company looking to launch their products into Brazil and Latin America."

STD Med, Inc. has also added both U.S. and International Contract Regulatory Consulting Services to their suite of offerings. The regulatory consulting service team will be managed by Christine Santagate , a seasoned engineering and quality professional with over 12 years of quality and regulatory (QR) experience. "I look forward to assisting STD Med customers by creating custom strategies to achieve regulatory compliance in this highly standardized industry" stated Ms. Santagate.  STD Med is being proactive in offering outsourced quality and regulatory processes as the industry shifts to more cost effective and capital efficient management of internal operations. Significant cost savings and man-hour reductions can be achieved by engaging a contract regulatory consultant and STD Med, Inc. looks to provide a best in class quality and regulatory service offering.

About  STD Med, Inc.

STD Med, Inc. is a rapidly growing and emerging leader in the development and manufacture of medical devices and precision machined components. Established in 1953, STD Med, Inc. is a privately held company with 3 facilities in Massachusetts which are ISO 13485:2003, ISO 9001:2008, JPAL and FDA approved. Over the past several years STD Med, Inc. has incubated and invested in several new technologies including Angiolink Corporation (acquired by Medtronic), Arthrosurface Inc., Spirus Medical, Inc.(acquired by Olympus), Cardiosolutions, Inc. and Saphena Medical and it is our intention to continue to pursue disruptive innovation in the medical device marketplace. Contact: Ron Murphy 508-942-8477 rmurphy@stdmed.com


'/>"/>
SOURCE STD Med, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroSigma Receives Health Canada Approval for Its Monarch eTNS System for the Treatment of Drug-Resistant Epilepsy and Major Depressive Disorder
2. Scioderms SD-101 Receives Breakthrough Therapy Designation from FDA for Treatment of Epidermolysis Bullosa
3. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
4. drchrono Receives Investment from Box
5. InspireMD Receives Approval From US Food and Drug Administration to Begin US Regulatory Trial
6. iBio, Inc. receives Notice from NYSE MKT Staff that Company currently is not in compliance with an additional Continued Listing Standard
7. Idaho Primary Care Association Receives Cambia Health Foundation grant for "Idaho Patient-Centered Medical Home" development in Idaho Community Health Centers
8. ARMGO Pharma Receives $1 Million Award from MDA to Support Advancement of Rycal Compound ARM210 as a Novel Treatment for Duchenne Muscular Dystrophy
9. Prostate Cancer Patient Receives First Treatment Using Latest Version of Vitesse Real-Time Brachytherapy Planning System from Varian Medical Systems
10. Sophono Alpha 2 Hearing System Receives FDA Clearance for Use With MRI
11. Rotech Receives Approval of First Day Motions; Approvals Ensure Operations Continue Normally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 The Rebound mobile app is poised to ... the tide of prescription drug addiction. The app empowers users ... and stepping down their dosage in a safe, controlled manner ... 2017; the first 100,000 people to sign up will enjoy ... ...
(Date:9/27/2017)... , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading ... announced that its MyDario product is expected to appear on The Dr. ... The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show ... The segment ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has released ... understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a picture ... Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that is ...
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... On ... holding a treadmill relay – Miles by Moonlight to raise money for the American ... $300 or more. , Teams will work together to keep their treadmills moving ...
Breaking Medicine News(10 mins):